Warfarin and vitamin K intake in the era of pharmacogenetics

Yael Lurie, Ronen Loebstein, Daniel Kurnik, Shlomo Almog, Hillel Halkin

Research output: Contribution to journalReview articlepeer-review

Abstract

The considerable variability in the warfarin dose-response relationship between individuals, is explained mainly by genetic variation in its major metabolic (CYP2C9) and target (VKORC1) enzymes. Despite the predominance of pharmacogenetics, environmental factors also affect the pharmacokinetics and pharmacodynamics of warfarin, and are often overlooked. Among these factors, dietary and supplemental vitamin K consumption is a controllable contributor to within-, and between-patient variability of warfarin sensitivity. In this commentary we review the current role of vitamin K in warfarin anticoagulation therapy, with emphasis on the following: 1 The effect of dietary and supplemental vitamin K on warfarin anticoagulation, beyond the impact of genetic variability in CYP2C9 and VKORC1. We deal separately with the effects of vitamin K on warfarin dose requirements during the induction of therapy, as opposed to its effect on stability of anticoagulation control during maintenance therapy. 2 The role of vitamin K supplementation in warfarin treated patients with vitamin K deficiency as well as in patients with unstable warfarin anticoagulation, and 3 The role of therapeutic vitamin K in cases of warfarin over-anticoagulation.

Original languageEnglish
Pages (from-to)164-170
Number of pages7
JournalBritish Journal of Clinical Pharmacology
Volume70
Issue number2
DOIs
StatePublished - Aug 2010

Keywords

  • genotype
  • pharmacogenetics
  • vitamin K
  • warfarin

Fingerprint

Dive into the research topics of 'Warfarin and vitamin K intake in the era of pharmacogenetics'. Together they form a unique fingerprint.

Cite this